Drug-drug interaction potential of antitumor acridine agent C-1748: The substrate of UDP-glucuronosyltransferases 2B7, 2B17 and the inhibitor of 1A9 and 2B7

Anna Mróz; Izabela Ryska; Hanna Sominka; Anna Bejrowska; Zofia Mazerska

doi:10.1016/j.pharep.2018.03.007

Drug-drug interaction potential of antitumor acridine agent C-1748: The substrate of UDP-glucuronosyltransferases 2B7, 2B17 and the inhibitor of 1A9 and 2B7

Abstrakt

Background The compound 9-(2′-hydroxyethylamino)-4-methyl-1-nitroacridine (C-1748), the promising antitumor agent developed in our laboratory was determined to undergo phase I metabolic pathways. The present studies aimed to know its biotransformation with phase II enzymes – UDP-glucuronosyltransferases (UGTs) and its potential to be engaged in drug-drug interactions arising from the modulation of UGT activity. Methods UGT-mediated transformations with rat liver (RLM), human liver (HLM), and human intestine (HIM) microsomes and with 10 recombinant human isoenzymes were investigated. Studies on the ability of C-1748 to inhibit UGT were performed with HLM, HT29 colorectal cancer cell homogenate and the selected recombinant UGT isoenzymes. The reactions were monitored using HPLC-UV/Vis method and the C-1748 metabolite structure was determined with ESI-TOF-MS/MS analysis. Results Pseudo-molecular ion (m/z 474.1554) and the experiment with β-glucuronidase indicated that O-glucuronide of C-1748 was formed in the presence of microsomal fractions. This reaction was selectively catalyzed by UGT2B7 and 2B17. High inhibitory effect of C-1748 was shown towards isoenzyme UGT1A9 (IC50=39.7μM) and significant but low inhibitory potential was expressed in HT29 cell homogenate (IC50=84.5μM). The mixed-type inhibition mechanism (Ki=17.0μM;Ki’=81.0μM), induced by C-1748 was observed for recombinant UGT1A9 glucuronidation, whereas HT29 cell homogenate resulted in noncompetitive inhibition (Ki=94.6μM). Conclusions The observed UGT-mediated metabolism of C-1748 and its ability to inhibit UGT activity should be considered as the potency for drug resistance and drug-drug interactions in the prospective multidrug therapy

Cytowania

6

CrossRef
0

Web of Science
5

Scopus

Autorzy (5)

Cytuj jako

Pełna treść

pobierz publikację

pobrano 30 razy

Wersja publikacji: Accepted albo Published Version
DOI:: Cyfrowy identyfikator dokumentu elektronicznego (otwiera się w nowej karcie) 10.1016/j.pharep.2018.03.007
Licencja: otwiera się w nowej karcie

pełna treść artykułu zobacz w serwisie zewnętrznym otwiera się w nowej karcie

Słowa kluczowe

Informacje szczegółowe

Kategoria:

Publikacja w czasopiśmie

Typ:

artykuł w czasopiśmie wyróżnionym w JCR

Opublikowano w:

Pharmacological Reports nr 70, wydanie 5, strony 972 - 980,
ISSN: 1734-1140

Język:

angielski

Rok wydania:

2018

Opis bibliograficzny:

Mróz A., Ryska I., Sominka H., Bejrowska A., Mazerska Z.: Drug-drug interaction potential of antitumor acridine agent C-1748: The substrate of UDP-glucuronosyltransferases 2B7, 2B17 and the inhibitor of 1A9 and 2B7// Pharmacological Reports. -Vol. 70, iss. 5 (2018), s.972-980

DOI: